Nouvelle déclaration d'incident
No de la demande: 2019-3170
Numéro de référence du titulaire d'homologation: USA-BAYERBAH-2019-US0026777 (Report 568166)
Nom du titulaire (nom légal complet, aucune abbréviation): Bayer inc
Adresse: 2920 Matheson Blvd
Ville: Mississaugua
État: ON
Pays: Canada
Code postal /Zip: L4W 5R6
Incident chez un animal domestique
Pays: UNITED STATES
État: OHIO
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 11556-155
Nom du produit: Seresto Large Dog (Flumethrin-Imidacloprid) Collar
Autre (préciser)
COLLAROui
Autres unités: COLLAR
Site: Animal / Usage sur un animal domestique
Autre
Dog / Chien
Mastiff canine
1
Homme
5
81.647
kg
Cutanée
>15 min <=2 hrs / >15 min <=2 h
>30 min <=2 hrs / >30 min <=2 h
Système
Unknown / Inconnu
Non
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
Approximately 30 minutes post application, the dog exhibited difficulty breathing on inhalation, lip licking, vomiting foam, coughing, gagging, and vocalization. The dog struggled to stand and was stretching his legs out (behavioral disorder). The collar was removed about 5 minutes after onset of the clinical signs. The dog was bathed with dish washing detergent and the signs resolved. Approximately 45 minutes post application, the dog began shaking for 30 seconds, had ataxia, and had a head tilt to the right. The dog was put in a kennel for observation. Approximately 4 hours post application, the dog recovered. On 30 May 2019, the dog was laterally recumbent and unresponsive when called. The dog was leashed and walked out of his kennel, then acutely died. No necropsy was performed.
Mort
O - Unclassifiable/unassessable Reported digestive disorders are unspecific and may have numerous other causes (e.g. gastrointestinal infection, dietary incompatibility) but mild gastrointestinal signs may occur shortly after product application. Reported respiratory disorders are not expected after collar application and may be associated with digestive disorders. Vocalization is likely related to earlier described signs. Unknown if collar perhaps was fitted to tightly. Reported neurological signs are not typically seen with appropriate topical product administration. Even with oral product exposure which was not reported only transient gastrointestinal signs are expected. Especially serious neurological disorder like unresponsiveness is not expected. Reported behavioural disorder and shaking are likely associated with neurological signs. Further reported lateral recumbency and sudden death are not expected as well following appropriate topical product application as inconsistent with product's pharmacological profile. Oral exposure to the collar is not expected to cause serious signs either. Product has wide margin of safety. Signs occurred after removal of collar and bathing of dog. No information medical history and necropsy details provided. Other causes (e.g. an underlying condition, poisoning etc.) must be considered although not described. Time to onset is short. Considering all aspects, a product relation is unassessable.